Sparsentan is more effective at reducing proteinuria, a measure of severity of a rare kidney disease called focal segmental glomerulosclerosis (FSGS), according to the results of a study published in the Journal of the American Society of Nephrology and reported at the American Society of Nephrology’s Kidney Week 2018.

The study’s principal investigator, Howard Trachtman, MD, professor in the Department of Pediatrics and division director of pediatric nephrology at Hassenfeld Children’s Hospital at NYU Langone, reported that patients saw significant reductions in proteinuria after the eight-week trial compared with the current standard of care for this disease.

Read more from MedPage Today (registration required).